Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frasci, G.
Right arrow Articles by Comella, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frasci, G.
Right arrow Articles by Comella, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:355-358, 1999
© 1999 European Society for Medical Oncology

brief-report

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study

G. Frasci, N. Panza, P. Comella, G. Carteni, T. Guida, G. P. Nicolella, M. Natale, R. Lombardi, A. Apicella, C. Pacilio, A. Gravina, L. Lapenta and G. Comella

Division of Medical Oncology A and Department of Diagnostic Imaging, National Tumor Institute; Divisions of Medical Oncology and Pneumology Cardarelli Hospital Naples, Italy

G. Frasci, MD, Division of Medical Oncology A, National Tumor Institute, via Mariano Semmola, 80131, Naples Italy E-mail: gifrasei@sirio-oncology.it

Purpose: Paclitaxel (PTX) and topotecan (TPT) have shown promising antitumor activity in both ovarian cancer (OC) and small-cell lung cancer (SCLC) patients. This phase I study was aimed at determining the maximum tolerable dose (MTD) of TPT given weekly over 30 min in combination with fixed doses of cisplatin (CDDP) and (PTX), and with G-CSF support.

Patients and methods: Forty-four patients with OC (19) or SCLC (25), either chemo-naïve (20) or pretreated (24) received CDDP 40 mg/m2, PTX 85 mg/m2 (one-hour infusion) and escalating TPT doses (starting from 0.75 mg/m2) in a 30-min infusion in weekly administration. Filgrastim 5 mg/kg was administered on days 3 to 5 of each week.

Results: Eight different dose levels were tested for a total of 295 delivered cycles. The dose escalation was interrupted at the TPT dose of 2.50 mg/m2. No toxic deaths occurred in this study. Grade 3 to 4 neutropenia, thrombocytopenia, and anemia occurred in 15 patients (36 cycles), seven patients (15 cycles), and four patients (five cycles), respectively. Severe vomiting and diarrhoea occurred in seven and four patients. Peripheral neuropathy was recorded in 11 patients (42 cycles), but it was never severe. An overall 11 of 19 (58%) OC and 11 of 25 (44%) SCLC patients obtained objective responses. Eight patients showed complete responses (three OC and three SCLC). Among the 20 chemo-naiVe patients, 9 of 11 (82%) OC and seven of nine (78%) SCLC responded.

Conclusions: The CDDP/TPT/PTX weekly administration with filgrastim support represents a well-tolerated and active therapeutic approach in both chemo-naive and pretreated OC and SCLC patients. A weekly dose of TPT of 2.25 mg/m2 is recommended for the phase II study.

cisplatin, ovarian cancer, paclitaxel, small-cell lung cancer, topotecan, weekly regimen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. Ardizzoni
Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update
Oncologist, December 1, 2004; 9(suppl_6): 4 - 13.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Eckardt
Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer
Oncologist, December 1, 2004; 9(suppl_6): 25 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg
Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93
J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. L. Coleman
Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary
Oncologist, October 1, 2002; 7(90005): 46 - 55.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Weekly Topotecan: An Alternative to Topotecan's Standard Daily x 5 Schedule?
Oncologist, August 1, 2002; 7(4): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Fujimura, T. Hidaka, and S. Saito
Selective Inhibition of the Epidermal Growth Factor Receptor by ZD1839 Decreases the Growth and Invasion of Ovarian Clear Cell Adenocarcinoma Cells
Clin. Cancer Res., July 1, 2002; 8(7): 2448 - 2454.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al.
Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy
J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.